Lazabemide
![]() | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 103878-84-8 |
| PubChem (CID) | 71307 |
| IUPHAR/BPS | 6640 |
| ChemSpider | 64426 |
| UNII |
420HD787N9 |
| KEGG | D04681 |
| Chemical and physical data | |
| Formula | C8H10ClN3O |
| Molar mass | 199.64 g/mol |
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]
References
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
